ALNYLAM PHARMACEUTICALS, INC.【ALNY】Cash flow
Market cap
$51.9B
P/E ratio
| 2010/12 | 2011/12 | 2012/12 | 2013/12 | 2014/12 | 2015/12 | 2016/12 | 2017/12 | 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | |
| Depreciation & amortization | 5 | 5 | 9 | 10 | 12 | 19 | 15 | 13 | 6 | 17 | 35 | 48 | 44 | 54 | 57 |
| Stock-based compensation | 19 | 17 | 12 | 21 | 33 | 46 | 76 | 93 | 158 | 175 | 140 | 166 | 231 | 222 | 272 |
| Cash from operations | -84 | -87 | -116 | -69 | -166 | -189 | -308 | -383 | -563 | -278 | -615 | -642 | -541 | 104 | -8 |
| Capital expenditures | -5 | -1 | -8 | -4 | -9 | -13 | -65 | -104 | -127 | -140 | -70 | -76 | -72 | -62 | -34 |
| Cash from investing | 18 | 82 | 3 | -131 | -549 | -321 | 143 | -290 | 273 | -418 | -436 | -273 | 169 | -336 | -117 |
| Cash from financing | 4 | 1 | 93 | 201 | 736 | 616 | 178 | 1,125 | 65 | 823 | 995 | 1,247 | 426 | 172 | 294 |
| Free cash flow | |||||||||||||||
| FCF margin (%) | - | - | - | - | - | - | - |